Imbelloni Luiz Eduardo, Neto Savino Gasparini, Ganem Eliana Marisa
Instituto de Anestesia Regional, Hospital São Bernardo, Rio de Janeiro.
Rev Bras Anestesiol. 2010 Sep-Oct;60(5):537-43. doi: 10.1016/S0034-7094(10)70065-9.
Better control of the level, intensity, and duration of spinal analgesia represents the greatest advantages of continuous spinal anesthesia. With the advent of intermediate catheters (over-the-needle catheter) and its low incidence of headaches and neurological symptoms, the technique has been gaining credibility. The objective of this paper is to report the possible safety of the new catheter with a large dose of hyperbaric 0.5% bupivacaine with 1.6% glucose associated with hyperbaric 2% lidocaine with 1.6% glucose.
Male patient, 78 years old, 85 kg, 168 cm, physical status ASA III, with hypertension, coronary artery disease, and chronic renal failure. The patient was candidate for surgery for huge bilateral inguinal and umbilical hernias, being submitted to preoperative pneumoperitoneum for one week to stretch abdominal cavity. After venoclysis with an 18G catheter, he was monitored with cardioscope, non-invasive blood pressure, and pulse oximetry; he was sedated with 1 mg of midazolam and 100 μg of fentanyl intravenously, and placed in left lateral decubitus. He underwent continuous spinal anesthesia by a median puncture in L₃-L₄ with a set with a 27G cut-bevel needle and 22G catheter. The total dose of anesthetic used was 25mg of 0.5% bupivacaine (hyperbaric, with 1.6% glucose), 160 mg of 2% lidocaine (hyperbaric, with 1.6% glucose), and morphine (100 μg). The patient was followed-up until the 30th postoperative day without neurological complaints.
Recently, the poor distribution of the local anesthetic through the microcatheter was attributed as the cause of cauda equina syndrome. This case report showed that, with the administration of high doses of hyperbaric anesthetics through the new catheter, poor distribution or risk of cauda equina syndrome were not observed.
更好地控制脊髓麻醉的水平、强度和持续时间是连续脊髓麻醉的最大优势。随着中间导管(穿刺针导管)的出现及其低头痛和神经症状发生率,该技术越来越受到认可。本文的目的是报告新型导管与大剂量含1.6%葡萄糖的0.5%重比重布比卡因以及含1.6%葡萄糖的2%重比重利多卡因联合使用时可能的安全性。
男性患者,78岁,体重85kg,身高168cm,美国麻醉医师协会(ASA)身体状况分级为III级,患有高血压、冠状动脉疾病和慢性肾衰竭。该患者因双侧巨大腹股沟疝和脐疝拟行手术,术前进行了一周的气腹以扩张腹腔。使用18G导管进行静脉输液后,通过心脏监护仪、无创血压和脉搏血氧饱和度进行监测;静脉注射1mg咪达唑仑和100μg芬太尼使其镇静,然后置于左侧卧位。通过在L₃-L₄进行正中穿刺,使用配有27G斜口穿刺针和22G导管的套件进行连续脊髓麻醉。所用麻醉剂的总剂量为25mg的0.5%布比卡因(重比重,含1.6%葡萄糖)、160mg的2%利多卡因(重比重,含1.6%葡萄糖)和吗啡(100μg)。对患者进行随访直至术后第30天,未出现神经方面的主诉。
最近,局部麻醉药通过微导管分布不佳被认为是马尾综合征的原因。本病例报告表明,通过新型导管给予高剂量重比重麻醉剂时,未观察到分布不佳或马尾综合征风险。